Skip to main content
Equibles

Uri Weinberg

NovoCure Ltd (NVCR)

Equibles does not estimate personal net worth.

Get an email with a short summary when NovoCure Ltd publishes a filing, an earnings call transcript or a press release.

Get NVCR alerts

About Uri Weinberg

The proxy statement of NovoCure Ltd reports total compensation of $4,159,945 for Uri Weinberg in fiscal 2025, including a base salary of $541,102. Disclosed compensation is on record for 2 fiscal years. Uri Weinberg has spoken on 2 earnings calls across 1 company, most recently for NovoCure Ltd on October 29, 2026. NovoCure Ltd is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at NovoCure Ltd includes Asaf Danziger (CEO and Board Member), David Hung (CEO and Board Member), Frank Leonard (CEO and Board Member) and 7 others.

Uri Weinberg on recent calls

“So, the Panova 5 study is going to focus on our approved indication in pancreatic cancer, namely locally advanced unresectable patients. And it will incorporate the Verastem's G12D VS7375 inhibitor, Keras inhibitor, concomitantly with gencitabine, napotlitaxel, and, of course, Optium-Tax.”
Other, Q3 2026 Earnings Conference Call ·
“So, from a scientific perspective, we have been able to publish already that tt-field therapy in the preclinical setting led to the downregulation of CEMIC, which is a master regulator of cancer cell proliferation and metastasis.”
Other, Q2 2026 Earnings Conference Call ·

Affiliation history

Company network

Leadership on record at NovoCure Ltd

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 NovoCure Ltd (NVCR) $541,102 $4,159,945
2024 NovoCure Ltd (NVCR) $471,483 $5,055,906

Recent activity